Initiated Equal-Weight X

BCYC Bicycle Therapeutics

Stephens

$25

Initiated Outperform X

BCYC Bicycle Therapeutics

RBC Capital Mkts

$35

Downgrades Buy Neutral X

BCYC Bicycle Therapeutics

B. Riley Securities

$33 $28

Upgrades Neutral Buy X

BCYC Bicycle Therapeutics

B. Riley Securities

Initiated Outperform X

BCYC Bicycle Therapeutics

Cowen

Initiated Overweight X

BCYC Bicycle Therapeutics

Barclays

$30

Resumed Buy X

BCYC Bicycle Therapeutics

Canaccord Genuity

$60

Downgrades Buy Neutral X

BCYC Bicycle Therapeutics

B. Riley Securities

$62 $33

Resumed Overweight X

BCYC Bicycle Therapeutics

Cantor Fitzgerald

$100 $80

Initiated Outperform X

BCYC Bicycle Therapeutics

SVB Leerink

$70

Initiated Buy X

BCYC Bicycle Therapeutics

Needham

$85

Initiated Mkt Outperform X

BCYC Bicycle Therapeutics

JMP Securities

$53

Initiated Buy X

BCYC Bicycle Therapeutics

Canaccord Genuity

$22

Initiated Neutral X

BCYC Bicycle Therapeutics

Goldman

$14

Initiated Buy X

BCYC Bicycle Therapeutics

Jefferies

$22

Initiated Overweight X

BCYC Bicycle Therapeutics

Piper Jaffray

$20

BCYC  Bicycle Therapeutics Limited

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.